ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
Karin Enell Smith(Alligator Bioscience (Sweden)), Peter Ellmark(Alligator Bioscience (Sweden))
Cited by 8
Related Papers
First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies
|International Journal of Cancer|2019|142